Introduction: Polycystic ovary syndrome (PCOS) affects 5–10% of women in reproductive age. It is associated with metabolic syndromes and non-metabolic disorders. Women with PCOS have dyslipidemia and oxidative stress representated by elevated serum Malonaldehyde (MDA) levels. These features are risk factors for development of atherogenesis and cardiovascular disease (CVD).
Materials and methods: A case-control study was conducted at the Department of Biochemistry, Koppal Institute of Medical Sciences, Koppal, India. It included 100 diagnosed PCOS patients (50- obese and 50 non-obese) and 100 controls (50-obese and 50 non-obese) in the age group of 18-40 years. The mean±SD were compared using student‘t’ – Test from the SPSS Statistics Data Editor version 21. Kruskal–Wallis test was employed for p values. The p value of <0.05 is considered statistically significant.
Results: Serum levels of total cholesterol, serum triglyceride, LDL, VLDL were higher in women with PCOS irrespective of BMI with p value of <0.001.There were low levels of serum HDL in women with PCOS irrespective of BMI with p value of <0.001. Serum MDA levels were higher in women with PCOS irrespective of BMI with p value of <0.001.
Conclusion: Dyslipidemia and increased OS indicated by elevated levels of MDA are seen in women with PCOS irrespective of BMI. Hence, PCOS women should be evaluated for lipid profile and oxidative stress and should be treated with antioxidant supplementation, which can be beneficial in preventing coronary vascular diseases.
Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reproductive biology and endocrinology. 2014;12(89):1-6.
Kitzinger C, Willmott J. ‘The thief of womanhood’: women’s experience of polycystic ovarian syndrome. Social science and medicine. 2002; 54(3):349-361.
Castro AV, Kolka CM, Kim SP, Bergman RN. Obesity, insulin resistance and comorbidities? Mechanisms of association. Arquivosbrasileiros de endocrinologia e metabologia. 2014;58(6):600-609.
Velez LM & Motta AB. Association between polycystic ovary syndrome and metabolic syndrome. Current medicinal chemistry. 2014; 21(35):3999-4012.
DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14(3):173-194.
Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endo Crinol. 2005;3(28):1-21.
Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34:407-413.
Mahfouz R, Sharma R, Sharma D, Sabanegh E, Agarwal A. Diagnostic value of the total antioxidant capacity (TAC) in human seminal plasma. Fertil Steril 2009; 91(3):805-811.
Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. The Cochrane database of systematic reviews. 2011;2:7-10.
Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome 2011;7:58-65.
Huber-Buchholz MM & Norman RJ. Restoration of Reproductive Potential by Lifestyle Modification in Obese Polycystic Ovary Syndrome: Role of Insulin Sensitivity and Luteinizing Hormone. The Journal of Clinical Endocrinology & Metabolism. 2013;84(4):1470-1474.
Zuo T, Zhu M, Xu W. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. Oxidative Medicine and Cellular Longevity. 2016;1:1-15.
Desai V, Prasad NR, Manohar SM, Sachan A, Lakshmi Narasimha SRP, Bitla ARR. Oxidative Stress in Non-Obese Women with Polycystic Ovarian Syndrome. Journal of Clinical and Diagnostic Research. 2014; 8(7): 1-3.
Karabulut AB, Cakmak M, Kiran RT, Sahin I. Oxidative Stress Status, Metabolic Profile and Cardiovascular Risk Factors in Patients with Polycystic Ovary Syndrome. Medicine Science. 2012;1(1):27-34.
Valkenburg TO, Regine PM, Theunissen S, Huberdina PM, Smedts, Dallinga-Thie GM et al. A More Atherogenic Serum Lipoprotein Profile Is Present in Women with Polycystic Ovary syndrome: A Case-Control Study. J Clin Endocrinol Metab. February 2008; 93(2):470-476.
Macut D, Panidis D, Glisic B, Spanos N, Petakov M, Bjekic J, Bozic I, Damjanovic S. Relation of proatherogenic lipid profile and insulin resistance in PCOS. Endocrine Abstracts. 2008;16:646-652.
Kalra A, Nair S, Rai L. Association of obesity and insulin resistance with dyslipidemia in Indian women with polycystic ovarian syndrome. Indian journal of medical sciences 2006;60(11):447-453.
Unni NC, Sumithra, Lakshmi RL, Menon NL, Subhakumari KN, Sheejamol VS. Evaluation of Oxidative Stress and hsCRP in Polycystic Ovarian Syndrome in a Tertiary Care Hospital. Ind J Clin Biochem. 2015;30(2):161-166.
Deba1 Z, Jambale TA, Gangadhara Swamy PM, Murthy DSJ. Study of levels of malondialdehyde, super oxide dismutase and hsCrp in serum of non-obese patients with polycystic ovarian syndrome . International Journal of Clinical Biochemistry and Research. 2017; 4(2):191-194.
Mandal B, Bandyopadhyay R, Chakrabarti S, Bandyopadhyay TK. Assessment of Oxidative stress in Patients of Diabetes Mellitus with and without Complications. Journal of Indian Academy of Clinical Medicine. 2010;11(1):20-25.
Zhang D, Luo WY, Liao H, Wang CF, Sun Y. The effects of oxidative Stress to PCOS. Sichuan Da Xue Xue Bao Yi Xue Ban 2008; 39(3):421-423.
Palacio JR, Iborra A, Ulcova-Gallova Z, Badia R, Martinez P. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clin Exp Immunol 2006; 144(2): 217-222.
Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80(1):123-127.